In this review:
Clinical implications of the metastatic environment of breast cancer
Genomics and choice of adjuvant breast cancer treatments
Risk stratification and treatment choices
Trastuzumab subcutaneous vs intravenous: time savings
Everolimus plus exemestane first line in advanced breast cancer
Effects of delaying adjuvant chemotherapy on survival outcomes
Risk-reducing mastectomy and overall survival in BRCA1/2 disease
Aromatase inhibitor pain syndromes
Margin width and survival in triple negative breast cancer
Letrozole: magnitude of benefit in BIG 1-98
Please login below to download this issue (PDF)